Research programme: inhibitors of peptide deformylase and Mur pathway enzymes - Novartis/Pfizer
Alternative Names: 415; LBM-415; NVP-PDF-713; PDF7; VIC-104959; VRC 3852; VRC-3324; VRC-3375; VRC-4307; VRC-4887Latest Information Update: 13 Mar 2008
At a glance
- Originator Novartis; Pfizer
- Class Hydroxamic acids; Peptides
- Mechanism of Action Cell wall inhibitors; Peptide deformylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Community-acquired pneumonia
Most Recent Events
- 11 Sep 2005 Vicuron Pharmaceuticals has been acquired and merged into Pfizer
- 04 Mar 2005 Suspended - Phase-I for Community-acquired pneumonia in USA (unspecified route)
- 16 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Bacterial infections antimicrobial activity, pharmacodynamics and pharmacokinetics section ,,,